Slide Presentation of the 2007 Annual Meeting of AHRQ

Comparative Effectiveness (continued)

• How should it be linked to coverage decisions by payers?
  • Should not serve the cost containment concerns of payers
  • Might be most useful in informing treatment options and assigning appropriate reimbursement premiums
• How should this information be communicated?
  • Share widely with all stakeholders, particularly providers and patients
  • Consider the dangers of incomplete understanding of results, particularly when communicated in an overly simplistic manner
  • Acknowledge that CE information can be incomplete, misleading, or misinterpreted
• How should stakeholders be involved?
  • Participate in framing the methods that will be used and prioritizing the key therapeutic areas
  • Promote transparency about the processes, findings, limitations, and appropriate uses of the information